BioMarin, Regeneron, Sanofi other news

BioMarin said it sold a Priority Review voucher to Regeneron and partner Sanofi for $67.5 million. BioMarin gained the voucher earlier this year following FDA’s approval of the company’s Vimizim elosulfase alfa to treat mucopolysaccharidosis IVA (MPS-IVA, Morquio’s syndrome). BioMarin was the first company to receive a voucher under the agency’s Rare Pediatric Disease Priority Review Voucher program, which was created by PDUFA V to encourage the development of new drugs and biologics to prevent and treat rare pediatric diseases. The program will sunset one year after the third voucher is awarded (see BioCentury, Feb. 17). ...